It will manufacture pen like delivery devices for people with diabetes in India and other parts of the world.
According to media reports, Kiran Mazumdar-Shaw, Chairperson & Managing Director, Biocon said that the company aims to provide insulin products to at least one in five insulin-dependent diabetes patients, anywhere in the world. This new device facility is a key milestone in our journey towards that goal.
She also added that this facility will enable them to not only fulfill our commitment to ‘Make in India for the world’ but also promise of affordable access to healthcare for all.
The product Basalog One will be providing a high end patient-friendly basal insulin glargine pen in India first and subsequently in the global markets, added reports.